Pricing Log in Create free account
Saturday 17 October 2026 Export PFE’s income statement to Excel — free account

Pfizer Inc.

PFE Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

29.58 0.14 +0.48%
Market cap
$167.8B
P/E
38.9×
Fwd P/E
12.2×
Dividend yield
5.81%
F-score
6/9
Altman Z
2.03
Beneish M
−2.52
Dividend safety
28/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Pfizer Inc. (PFE) Price to free cash flow

Alert me on Price to free cash flow

As of 16 October 2026, Pfizer Inc. (PFE) trades at a price to free cash flow of 16.5×. Over the past ten years it has ranged from 8.0× (October 2021) to 44.3× (July 2024); the current reading is higher than 67% of that period. That is in line with the Drug Manufacturers General industry median of 16.5× and below the Healthcare sector median of 20.2×.

Price to free cash flow, daily

Embed this chart

Annual newest first

Period Price to free cash flow Change
FY2025 17.1× 2.82%
FY2024 16.6× (60.41%)
FY2023 42.0× 268.69%
FY2022 11.4× 0.14%
FY2021 11.4× (36.69%)
FY2020 18.0× (12.10%)
FY2019 20.4× 15.12%
FY2018 17.8× 24.82%
FY2017 14.2× 5.54%
FY2016 13.5× (5.99%)

Quarterly newest first

Period Price to free cash flow Change
Jun 2026 13.5× (26.79%)
Mar 2026 18.4× 7.62%
Dec 2025 17.1× 13.05%
Sep 2025 15.1× 27.75%
42 more quarters

Against its own ten years

Low 8.0× High 44.3×
Ten-year median 14.9×
Current reading's percentile 67

Price to free cash flow against peers

Company Price to free cash flow
SNY Sanofi compare 6.7×
BMY Bristol Myers Squibb Company compare 10.7×
GSK GSK PLC Sponsored ADR compare 13.0×
GILD Gilead Sciences, Inc. compare 15.0×
PFE Pfizer Inc. 16.5×
NVS Novartis AG compare 18.9×
NVO Novo Nordisk A/S compare 22.6×
AMGN Amgen Inc. compare 24.0×
AZN AstraZeneca PLC compare 40.9×
Drug Manufacturers General industry median 16.5×
Healthcare sector median 20.2×
Market median 14.2×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on PFE